Abstract
The recent spread of COVID-19 across the U.S. led to concerted efforts by states to flatten the curve through the adoption of stay-at-home mandates that encourage individuals to reduce travel and maintain social distance. Combining data on changes in travel activity with COVID-19 health outcomes and state policy adoption timing, we characterize nationwide changes in mobility patterns, isolate the portion attributable to statewide mandates, and link these reductions to changes in COVID-19 health outcomes. We find evidence of dramatic nationwide declines in mobility prior to adoption of any statewide mandates. Once states adopt a mandate, we estimate further mandate-induced declines between 2.1 and 7.0 percentage points relative to pre-COVID-19 baseline levels. Controlling for pre-treatment changes in mobility, we estimate mandate-induced declines of 0.13-0.17 fewer deaths and 5.6-6 fewer hospitalizations per 100,000 residents, equivalent to 23-30,000 averted deaths in adopting states for the months of March and April and death rates 42-54% lower than in the absence of policies. These estimates represent a likely lower bound on the health impacts of stay-at-home mandates, and our findings for the health impacts of early mobility reductions convey important policy implications for re-opening.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
none
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version was updated due to peer review process resubmission to the journal.
Data Availability
Data used for this analysis are from Unacast, Health Data are from the COVID 19 Tracking project, and policy data from The New York Times, and COVID-19 US state policy databases.
